---
authors:
- Ebell, Mark H
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38393811/
file_path: 2024/02/esketamine-is-superior-to-quetiapine-for-remission-of-treatm.md
issue: '2'
keywords:
- Ketamine
- Humans
- Antidepressive Agents
- Depression
- Quetiapine Fumarate
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Quetiapine Fumarate
- Depression
- Antidepressive Agents
- Ketamine
original_format: PubMed
pages: Online
patient_population: Adults
peer_reviewed: true
pmid: '38393811'
processed_date: '2025-07-30'
publication_date: '2024-02-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression.
topics:
- Depression
- Psychiatry
- Family Medicine
- Mental Health
volume: '109'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '38393811'
  title: Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant
    Depression.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
    affiliation: Professor, University of Georgia, Athens, Ga.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '109'
    issue: '2'
  publication_info:
    year: '2024'
    month: '02'
    full_date: '2024-02-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Quetiapine Fumarate
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Depression
    major_topic: true
  - descriptor: Antidepressive Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Ketamine
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  publication_types: *id001
related_articles:
- pmid: '38393811'
  title: Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant
    Depression.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Feb
- pmid: '37792613'
  title: Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
  authors:
  - name: Reif A
    authtype: Author
    clusterid: ''
  - name: Bitter I
    authtype: Author
    clusterid: ''
  - name: Buyze J
    authtype: Author
    clusterid: ''
  - name: Cebulla K
    authtype: Author
    clusterid: ''
  - name: Frey R
    authtype: Author
    clusterid: ''
  - name: Fu DJ
    authtype: Author
    clusterid: ''
  - name: Ito T
    authtype: Author
    clusterid: ''
  - name: Kambarov Y
    authtype: Author
    clusterid: ''
  - name: Llorca PM
    authtype: Author
    clusterid: ''
  - name: Oliveira-Maia AJ
    authtype: Author
    clusterid: ''
  - name: Messer T
    authtype: Author
    clusterid: ''
  - name: Mulhern-Haughey S
    authtype: Author
    clusterid: ''
  - name: Rive B
    authtype: Author
    clusterid: ''
  - name: von Holt C
    authtype: Author
    clusterid: ''
  - name: Young AH
    authtype: Author
    clusterid: ''
  - name: Godinov Y
    authtype: Author
    clusterid: ''
  - name: ESCAPE-TRD Investigators
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2023 Oct 5
- pmid: '37851473'
  title: Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression.
  authors:
  - name: Harris E
    authtype: Author
    clusterid: ''
  source: JAMA
  pubdate: 2023 Nov 7
- pmid: '38954874'
  title: Safety and tolerability of esketamine nasal spray versus quetiapine extended
    release in patients with treatment resistant depression.
  authors:
  - name: McIntyre RS
    authtype: Author
    clusterid: ''
  - name: Bitter I
    authtype: Author
    clusterid: ''
  - name: Buyze J
    authtype: Author
    clusterid: ''
  - name: Fagiolini A
    authtype: Author
    clusterid: ''
  - name: Godinov Y
    authtype: Author
    clusterid: ''
  - name: Gorwood P
    authtype: Author
    clusterid: ''
  - name: Ito T
    authtype: Author
    clusterid: ''
  - name: Oliveira-Maia AJ
    authtype: Author
    clusterid: ''
  - name: Vieta E
    authtype: Author
    clusterid: ''
  - name: Werner-Kiechle T
    authtype: Author
    clusterid: ''
  - name: Young AH
    authtype: Author
    clusterid: ''
  - name: Reif A
    authtype: Author
    clusterid: ''
  source: Eur Neuropsychopharmacol
  pubdate: 2024 Aug
- pmid: '38169504'
  title: Esketamine Nasal Spray versus Quetiapine for Resistant Depression. Reply.
  authors:
  - name: Reif A
    authtype: Author
    clusterid: ''
  - name: Mulhern-Haughey S
    authtype: Author
    clusterid: ''
  - name: Godinov Y
    authtype: Author
    clusterid: ''
  source: N Engl J Med
  pubdate: 2024 Jan 4
---

# Esketamine Is Superior to Quetiapine for Remission of Treatment-Resistant Depression.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 109, No. 2 | 2024-02-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38393811/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Depression, Psychiatry, Family Medicine, Mental Health

## MeSH Terms

Humans, Quetiapine Fumarate, Depression, Antidepressive Agents, Ketamine

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38393811/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
